Current status of molecularly targeted therapy for hepatocellular carcinoma: Basic science

International Journal of Clinical Oncology

Volumn 15, Issue 3, 2010, Pages 235-241

  Tanaka, Shinji ^a   Arii, Shigeki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Aurora; Growth signals; Mitotic stress; Synthetic lethality

Indexed keywords

2 [[3 [4 [5 [2 (3 FLUOROANILINO) 2 OXOETHYL] 1H PYRAZOL 3 YLAMINO] 7 QUINAZOLINYLOXY]PROPYL](ETHYL)AMINO]ETHYL DIHYDROGEN PHOSPHATE; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 [1 (3 FLUOROBENZYL) 5 INDAZOLYLAMINO] 5 METHYLPYRROLO[2,1 F][1,2,4]TRIAZINE 6 CARBAMIC ACID 3 MORPHOLINOMETHYL ESTER; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; AURORA KINASE INHIBITOR; BELINOSTAT; BEVACIZUMAB; BORTEZOMIB; BRIVANIB; CEDIRANIB; CETUXIMAB; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTOSTATIC AGENT; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMC 1121B; IMC A 12; LAPATINIB; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; NEXABAR; PHA 680632; PI 88; RAF PROTEIN; RAMUCIRUMAB; RAPAMYCIN; RAPAMYCIN DERIVATIVE; SORAFENIB; SU 6688; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; ANGIOGENESIS; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; LETHALITY; LIVER CELL CARCINOMA; MITOTIC STRESS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRESS; SYNTHETIC LETHALITY; ANIMAL; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; LIVER NEOPLASMS; METABOLISM; MITOSIS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; HUMANS; LIVER NEOPLASMS; MITOSIS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 77955716927     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-010-0083-4     Document Type: Review

References (52)

1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57-70
2. Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13(6):472-482
3. Luo J, Solimini NL, Elledge SJ (2009) Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136(5):823-837
4. Weinstein IB (2002) Cancer. addiction to oncogenes-the Achilles heal of cancer. Science 297(5578):63-64
5. Weinstein IB, Joe AK (2006) Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3(8):448-457
6. Tanaka S, Arii S (2009) Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci 100(1):1-8
7. Llovet JM, Bruix J (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:1312-1327
8. Yau T, Chan P, Epstein R et al (2009) Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int 29(1):10-17 Review
9. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364
10. Tanaka S, Arii S (2006) Current status of perspective of antiangiogenic therapy for cancer; hepatocellular carcinoma. Int J Clin Oncol 11:82-89
11. Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2(10):795-803
12. Mise M, Arii S, Higashituji H et al (1996) Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 23(3):455-464
13. Schmitt M, Horbach A, Kubitz R et al (2004) Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion. J Hepatol 41(2):274-283
14. Kaplan RN, Riba RD, Zacharoulis S et al (2005) VEGFR1- positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature 438(7069):820-827
15. Hiratsuka S, Watanabe A, Aburatani H et al (2006) Tumourmediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 8(12):1369-1375
16. Arii S (2004) Role of vascular endothelial growth factor on the invasive potential of hepatocellular carcinoma. J Hepatol 41(2):333-335
17. Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22(10):1276-1312
18. Kuhnert F, Tam BY, Sennino B et al (2008) Soluble receptormediated selective inhibition of VEGFR and PDGFRbeta signaling during physiologic and tumor angiogenesis. Proc Natl Acad Sci USA 105(29):10185-10190
19. Uematsu S, Higashi T, Nouso K et al (2005) Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 20(4):583-588
20. Poon RT, Ng IO, Lau C et al (2001) Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg 182:298-304
21. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
22. Tanaka S, Mori M, Sakamoto Y et al (1999) Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Investig 103(3):341-345 (Pubitemid 29069983)
23. Tanaka S, Wands JR, Arii S (2006) Induction of angiopoietin-2 gene expression by COX-2: A novel role for COX-2 inhibitors during hepatocarcinogenesis. J Hepatol 44(1):233-235
24. Tanaka S, Sugimachi K, Yamashita Yi et al (2002) Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. Hepatology 35(4):861-867
25. Seegar TC, Eller B, Tzvetkova-Robev D et al (2010) Tie1-Tie2 interactions mediate functional differences between angiopoietin ligands. Mol Cell 37(5):643-655
26. Holash J, Maisonpierre PC, Compton D et al (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284(5422):1994-1998
27. Oliner J, Min H, Leal J et al (2004) Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6(5):507-516
28. Herbst RS, Hong D, Chap L et al (2009) Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 27(21):3557-3565
29. Pawson T (2004) Specificity in signal transduction: from phosphotyrosine- SH2 domain interactions to complex cellular systems. Cell 116:191-203
30. Tanaka S, Sugimachi K, Maehara S et al (2002) Oncogenic signal transduction and therapeutic strategy for hepatocellular carcinoma. Surgery 131:S142-S147
31. Schagdarsurengin U, Wilkens L, Steinemann D et al (2003) Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene 22:1866-1871
32. Farazi PA, DePinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6:674-687
33. Luo J, Manning BD, Cantley LC (2003) Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4:257-262
34. Chiang GG, Abraham RT (2007) Targeting the mTOR signaling network in cancer. Trends Mol Med 13:433-442
35. Foster KG, Fingar DC (2010) mTOR: conducting the cellular signaling symphony. J Biol Chem
36. Schvartzman JM, Sotillo R, Benezra R (2010) Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat Rev Cancer 10(2):102-115
37. Tanaka S, Arii S, Yasen M et al (2008) Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg 95:611-619
38. Keen N, Taylor S (2004) Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 4:927-936
39. Nguyen HG, Makitalo M, Yang D et al (2009) Deregulated Aurora-B induced tetraploidy promotes tumorigenesis. FASEB J 23(8):2741-2748
40. Harrington EA, Bebbington D, Moore J et al (2004) VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10(3):262-267
41. Aihara A, Tanaka S, Yasen M et al (2010) The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Hepatol 52(1):63-71
42. Tanaka S, Mogushi K, Yasen M et al (2010) Gene-expression phenotypes for vascular invasiveness of hepatocellular carcinomas. Surgery 147(3):405-414
43. Luo J, Emanuele MJ, Li D et al (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137(5):835-848
44. Dobzhansky T (1946) Genetics of natural populations. XIII. Recombination and variability in populations of Drosophila pseudoobscura. Genetics 31:269-290
45. Kaelin WG Jr (2005) The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5(9):689-698
46. Fong PC, Boss DS, Yap TA et al (2009) Inhibition of poly(ADPribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123-134
47. Iglehart JD, Silver DP (2009) Synthetic lethality-a new direction in cancer-drug development. N Engl J Med 361(2):189-191
48. Bryant HE, Schultz N, Thomas HD et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434(7035):913-917
49. Farmer H, McCabe N, Lord CJ et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917-921
50. Ince N, Wands JR (1999) The increasing incidence of hepatocellular carcinoma. N Engl J Med 340:798-799
51. Arii S, Yamaoka Y, Futagawa S et al (2000) Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 32:1224-1229
52. Tanaka S, Arii S (2010) Medical treatments: in association or alone, their role and their future perspectives: novel moleculartargeted therapy for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg